TGFB1 and familial pancreatic carcinoma: We reported that a glucosylceramide synthase inhibitor, N-(5-adamantane-1-yl-methoxy)-pentyl-1-deoxynojirimycin (AMP-dNM), reduced TGF-β1 signaling, presumably by inhibiting the interaction between GM2 and TGFβ receptor II by downregulating GM2, resulting in suppression of invasion in cancer stem cell (CSC)-like GM2 expressing pancreatic cancer cells [19].